Homepage
Author:
Wuxi Biologics
Posted Date:
May 27, 2026
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
Wuxi Biologics
May 27, 2026
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
Wuxi Biologics
May 12, 2026
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
Wuxi Biologics
April 29, 2026
WuXi Biologics Chengdu Microbial Commercial Manufacturing Site Achieves Structural Completion and Key Equipment Arrival
Wuxi Biologics
April 24, 2026
WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics
Wuxi Biologics
April 23, 2026
WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year
Wuxi Biologics
April 17, 2026
WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing
Wuxi Biologics
April 14, 2026
WuXi Biologics Honored with CDMO Leadership Awards for Ninth Consecutive Year
Wuxi Biologics
March 30, 2026
WuXi Biologics Reports Record 2025 Annual Results, Operational Excellence Driven by Digital-Native Architecture
Wuxi Biologics
March 25, 2026
WuXi Biologics Reports Record 2025 Annual Results
Wuxi Biologics
March 24, 2026
1
2
Next
